0
U.S. (TOLL FREE)
+1 (315) 215-3225
Automative

0
U.S. (TOLL FREE)
+1 (315) 215-3225
Global Rituxan (Rituximab) and Biosimilar Market Research Report 2023
Published Date: June 2023
|
Report Code: QYRE-Auto-2Z14941
Home | Market Reports | Business & Industrial| Pharmaceuticals & Biotech
Global Rituxan Rituximab and Biosimilar Market Research Report 2023
BUY CHAPTERS

Global Rituxan (Rituximab) and Biosimilar Market Research Report 2023

Code: QYRE-Auto-2Z14941
Report
June 2023
Pages:68
QYResearch
Buy Now with 15% Discount
DESCRIPTION
TABLE OF CONTENT
TABLES & FIGURES

Rituxan (Rituximab) and Biosimilar Market Size

According to QYResearch’s new survey, global Rituxan (Rituximab) and Biosimilar market is projected to reach US$ 5306.7 million in 2029, increasing from US$ 4125 million in 2022, with the CAGR of 3.5% during the period of 2023 to 2029.

Rituxan (Rituximab) and Biosimilar Market

Rituxan (Rituximab) and Biosimilar Market

RITUXAN® (rituximab) is a prescription medicine used to treat: Adults with Non-Hodgkin's Lymphoma (NHL): alone or with other chemotherapy medicines. Children 6 months of age and older with mature B-cell Non-Hodgkin's Lymphoma (NHL) and mature B-cell acute leukemia (B-AL): in combination with chemotherapy medicines.
Influencing issues, such as economy environments, COVID-19 and Russia-Ukraine War, have led to great market fluctuations in the past few years and are considered comprehensively in the whole Rituxan (Rituximab) and Biosimilar market research.
Key manufacturers engaged in the Rituxan (Rituximab) and Biosimilar industry include Roche, Teva, Pfizer and Amgen, etc. Among those manufacturers, the top 3 players guaranteed % supply worldwide in 2022.
When refers to consumption region, % volume of Rituxan (Rituximab) and Biosimilar were sold to North America, Europe and Asia Pacific in 2022. Moreover, China, plays a key role in the whole Rituxan (Rituximab) and Biosimilar market and estimated to attract more attentions from industry insiders and investors.

Report Scope

This report, based on historical analysis (2018-2022) and forecast calculation (2023-2029), aims to help readers to get a comprehensive understanding of global Rituxan (Rituximab) and Biosimilar market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.

Scope of Rituxan (Rituximab) and Biosimilar Market Report

Report Metric Details
Report Name Rituxan (Rituximab) and Biosimilar Market
Accounted market size in 2022 US$ 4125 million
Forecasted market size in 2029 US$ 5306.7 million
CAGR 3.5%
Base Year 2022
Forecasted years 2023 - 2029
Segment by Type
  • Brand
  • Biosimilar
Segment by Application
  • Child
  • Adult
Consumption by Region
  • North America (United States, Canada)
  • Europe (Germany, France, UK, Italy, Russia)
  • Asia-Pacific (China, Japan, South Korea, Taiwan)
  • Southeast Asia (India)
  • Latin America (Mexico, Brazil)
By Company Roche, Teva, Pfizer, Amgen
Forecast units USD million in value
Report coverage Revenue and volume forecast, company share, competitive landscape, growth factors and trends

FAQ for this report

How fast is Rituxan (Rituximab) and Biosimilar Market market growing?

Ans: The Rituxan (Rituximab) and Biosimilar Market market witnessing a CAGR of 3.5% during the forecast period 2023-2029.

What is the Rituxan (Rituximab) and Biosimilar Market market size in 2029?

Ans: According to QYResearch’s new survey, global Rituxan (Rituximab) and Biosimilar market is projected to reach US$ 5306.7 million in 2029, increasing from US$ 4125 million in 2022, with the CAGR of 3.5% during the period of 2023 to 2029.

1 Rituxan (Rituximab) and Biosimilar Market Overview
1.1 Product Overview and Scope of Rituxan (Rituximab) and Biosimilar
1.2 Rituxan (Rituximab) and Biosimilar Segment by Type
1.2.1 Global Rituxan (Rituximab) and Biosimilar Market Value Comparison by Type (2023-2029)
1.2.2 Brand
1.2.3 Biosimilar
1.3 Rituxan (Rituximab) and Biosimilar Segment by Application
1.3.1 Global Rituxan (Rituximab) and Biosimilar Market Value by Application: (2023-2029)
1.3.2 Child
1.3.3 Adult
1.4 Global Rituxan (Rituximab) and Biosimilar Market Size Estimates and Forecasts
1.4.1 Global Rituxan (Rituximab) and Biosimilar Revenue 2018-2029
1.4.2 Global Rituxan (Rituximab) and Biosimilar Sales 2018-2029
1.4.3 Global Rituxan (Rituximab) and Biosimilar Market Average Price (2018-2029)
1.5 Assumptions and Limitations
2 Rituxan (Rituximab) and Biosimilar Market Competition by Manufacturers
2.1 Global Rituxan (Rituximab) and Biosimilar Sales Market Share by Manufacturers (2018-2023)
2.2 Global Rituxan (Rituximab) and Biosimilar Revenue Market Share by Manufacturers (2018-2023)
2.3 Global Rituxan (Rituximab) and Biosimilar Average Price by Manufacturers (2018-2023)
2.4 Global Rituxan (Rituximab) and Biosimilar Industry Ranking 2021 VS 2022 VS 2023
2.5 Global Key Manufacturers of Rituxan (Rituximab) and Biosimilar, Manufacturing Sites & Headquarters
2.6 Global Key Manufacturers of Rituxan (Rituximab) and Biosimilar, Product Type & Application
2.7 Rituxan (Rituximab) and Biosimilar Market Competitive Situation and Trends
2.7.1 Rituxan (Rituximab) and Biosimilar Market Concentration Rate
2.7.2 The Global Top 5 and Top 10 Largest Rituxan (Rituximab) and Biosimilar Players Market Share by Revenue
2.7.3 Global Rituxan (Rituximab) and Biosimilar Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
2.8 Manufacturers Mergers & Acquisitions, Expansion Plans
3 Rituxan (Rituximab) and Biosimilar Retrospective Market Scenario by Region
3.1 Global Rituxan (Rituximab) and Biosimilar Market Size by Region: 2018 Versus 2022 Versus 2029
3.2 Global Rituxan (Rituximab) and Biosimilar Global Rituxan (Rituximab) and Biosimilar Sales by Region: 2018-2029
3.2.1 Global Rituxan (Rituximab) and Biosimilar Sales by Region: 2018-2023
3.2.2 Global Rituxan (Rituximab) and Biosimilar Sales by Region: 2024-2029
3.3 Global Rituxan (Rituximab) and Biosimilar Global Rituxan (Rituximab) and Biosimilar Revenue by Region: 2018-2029
3.3.1 Global Rituxan (Rituximab) and Biosimilar Revenue by Region: 2018-2023
3.3.2 Global Rituxan (Rituximab) and Biosimilar Revenue by Region: 2024-2029
3.4 North America Rituxan (Rituximab) and Biosimilar Market Facts & Figures by Country
3.4.1 North America Rituxan (Rituximab) and Biosimilar Market Size by Country: 2018 VS 2022 VS 2029
3.4.2 North America Rituxan (Rituximab) and Biosimilar Sales by Country (2018-2029)
3.4.3 North America Rituxan (Rituximab) and Biosimilar Revenue by Country (2018-2029)
3.4.4 United States
3.4.5 Canada
3.5 Europe Rituxan (Rituximab) and Biosimilar Market Facts & Figures by Country
3.5.1 Europe Rituxan (Rituximab) and Biosimilar Market Size by Country: 2018 VS 2022 VS 2029
3.5.2 Europe Rituxan (Rituximab) and Biosimilar Sales by Country (2018-2029)
3.5.3 Europe Rituxan (Rituximab) and Biosimilar Revenue by Country (2018-2029)
3.5.4 Germany
3.5.5 France
3.5.6 U.K.
3.5.7 Italy
3.5.8 Russia
3.6 Asia Pacific Rituxan (Rituximab) and Biosimilar Market Facts & Figures by Country
3.6.1 Asia Pacific Rituxan (Rituximab) and Biosimilar Market Size by Country: 2018 VS 2022 VS 2029
3.6.2 Asia Pacific Rituxan (Rituximab) and Biosimilar Sales by Country (2018-2029)
3.6.3 Asia Pacific Rituxan (Rituximab) and Biosimilar Revenue by Country (2018-2029)
3.6.4 China
3.6.5 Japan
3.6.6 South Korea
3.6.7 India
3.6.8 Australia
3.6.9 China Taiwan
3.6.10 Southeast Asia
3.7 Latin America Rituxan (Rituximab) and Biosimilar Market Facts & Figures by Country
3.7.1 Latin America Rituxan (Rituximab) and Biosimilar Market Size by Country: 2018 VS 2022 VS 2029
3.7.2 Latin America Rituxan (Rituximab) and Biosimilar Sales by Country (2018-2029)
3.7.3 Latin America Rituxan (Rituximab) and Biosimilar Revenue by Country (2018-2029)
3.7.4 Mexico
3.7.5 Brazil
3.7.6 Argentina
3.8 Middle East and Africa Rituxan (Rituximab) and Biosimilar Market Facts & Figures by Country
3.8.1 Middle East and Africa Rituxan (Rituximab) and Biosimilar Market Size by Country: 2018 VS 2022 VS 2029
3.8.2 Middle East and Africa Rituxan (Rituximab) and Biosimilar Sales by Country (2018-2029)
3.8.3 Middle East and Africa Rituxan (Rituximab) and Biosimilar Revenue by Country (2018-2029)
3.8.4 Turkey
3.8.5 Saudi Arabia
3.8.6 UAE
4 Segment by Type
4.1 Global Rituxan (Rituximab) and Biosimilar Sales by Type (2018-2029)
4.1.1 Global Rituxan (Rituximab) and Biosimilar Sales by Type (2018-2023)
4.1.2 Global Rituxan (Rituximab) and Biosimilar Sales by Type (2024-2029)
4.1.3 Global Rituxan (Rituximab) and Biosimilar Sales Market Share by Type (2018-2029)
4.2 Global Rituxan (Rituximab) and Biosimilar Revenue by Type (2018-2029)
4.2.1 Global Rituxan (Rituximab) and Biosimilar Revenue by Type (2018-2023)
4.2.2 Global Rituxan (Rituximab) and Biosimilar Revenue by Type (2024-2029)
4.2.3 Global Rituxan (Rituximab) and Biosimilar Revenue Market Share by Type (2018-2029)
4.3 Global Rituxan (Rituximab) and Biosimilar Price by Type (2018-2029)
5 Segment by Application
5.1 Global Rituxan (Rituximab) and Biosimilar Sales by Application (2018-2029)
5.1.1 Global Rituxan (Rituximab) and Biosimilar Sales by Application (2018-2023)
5.1.2 Global Rituxan (Rituximab) and Biosimilar Sales by Application (2024-2029)
5.1.3 Global Rituxan (Rituximab) and Biosimilar Sales Market Share by Application (2018-2029)
5.2 Global Rituxan (Rituximab) and Biosimilar Revenue by Application (2018-2029)
5.2.1 Global Rituxan (Rituximab) and Biosimilar Revenue by Application (2018-2023)
5.2.2 Global Rituxan (Rituximab) and Biosimilar Revenue by Application (2024-2029)
5.2.3 Global Rituxan (Rituximab) and Biosimilar Revenue Market Share by Application (2018-2029)
5.3 Global Rituxan (Rituximab) and Biosimilar Price by Application (2018-2029)
6 Key Companies Profiled
6.1 Roche
6.1.1 Roche Corporation Information
6.1.2 Roche Description and Business Overview
6.1.3 Roche Rituxan (Rituximab) and Biosimilar Sales, Revenue and Gross Margin (2018-2023)
6.1.4 Roche Rituxan (Rituximab) and Biosimilar Product Portfolio
6.1.5 Roche Recent Developments/Updates
6.2 Teva
6.2.1 Teva Corporation Information
6.2.2 Teva Description and Business Overview
6.2.3 Teva Rituxan (Rituximab) and Biosimilar Sales, Revenue and Gross Margin (2018-2023)
6.2.4 Teva Rituxan (Rituximab) and Biosimilar Product Portfolio
6.2.5 Teva Recent Developments/Updates
6.3 Pfizer
6.3.1 Pfizer Corporation Information
6.3.2 Pfizer Description and Business Overview
6.3.3 Pfizer Rituxan (Rituximab) and Biosimilar Sales, Revenue and Gross Margin (2018-2023)
6.3.4 Pfizer Rituxan (Rituximab) and Biosimilar Product Portfolio
6.3.5 Pfizer Recent Developments/Updates
6.4 Amgen
6.4.1 Amgen Corporation Information
6.4.2 Amgen Description and Business Overview
6.4.3 Amgen Rituxan (Rituximab) and Biosimilar Sales, Revenue and Gross Margin (2018-2023)
6.4.4 Amgen Rituxan (Rituximab) and Biosimilar Product Portfolio
6.4.5 Amgen Recent Developments/Updates
7 Industry Chain and Sales Channels Analysis
7.1 Rituxan (Rituximab) and Biosimilar Industry Chain Analysis
7.2 Rituxan (Rituximab) and Biosimilar Key Raw Materials
7.2.1 Key Raw Materials
7.2.2 Raw Materials Key Suppliers
7.3 Rituxan (Rituximab) and Biosimilar Production Mode & Process
7.4 Rituxan (Rituximab) and Biosimilar Sales and Marketing
7.4.1 Rituxan (Rituximab) and Biosimilar Sales Channels
7.4.2 Rituxan (Rituximab) and Biosimilar Distributors
7.5 Rituxan (Rituximab) and Biosimilar Customers
8 Rituxan (Rituximab) and Biosimilar Market Dynamics
8.1 Rituxan (Rituximab) and Biosimilar Industry Trends
8.2 Rituxan (Rituximab) and Biosimilar Market Drivers
8.3 Rituxan (Rituximab) and Biosimilar Market Challenges
8.4 Rituxan (Rituximab) and Biosimilar Market Restraints
9 Research Finding and Conclusion
10 Methodology and Data Source
10.1 Methodology/Research Approach
10.1.1 Research Programs/Design
10.1.2 Market Size Estimation
10.1.3 Market Breakdown and Data Triangulation
10.2 Data Source
10.2.1 Secondary Sources
10.2.2 Primary Sources
10.3 Author List
10.4 Disclaimer
List of Tables
    Table 1. Global Rituxan (Rituximab) and Biosimilar Market Value Comparison by Type (2023-2029) & (US$ Million)
    Table 2. Global Rituxan (Rituximab) and Biosimilar Market Value Comparison by Application (2023-2029) & (US$ Million)
    Table 3. Global Rituxan (Rituximab) and Biosimilar Market Competitive Situation by Manufacturers in 2022
    Table 4. Global Rituxan (Rituximab) and Biosimilar Sales (K Units) of Key Manufacturers (2018-2023)
    Table 5. Global Rituxan (Rituximab) and Biosimilar Sales Market Share by Manufacturers (2018-2023)
    Table 6. Global Rituxan (Rituximab) and Biosimilar Revenue (US$ Million) by Manufacturers (2018-2023)
    Table 7. Global Rituxan (Rituximab) and Biosimilar Revenue Share by Manufacturers (2018-2023)
    Table 8. Global Market Rituxan (Rituximab) and Biosimilar Average Price (US$/Unit) of Key Manufacturers (2018-2023)
    Table 9. Global Key Players of Rituxan (Rituximab) and Biosimilar, Industry Ranking, 2021 VS 2022 VS 2023
    Table 10. Global Key Manufacturers of Rituxan (Rituximab) and Biosimilar, Manufacturing Sites & Headquarters
    Table 11. Global Key Manufacturers of Rituxan (Rituximab) and Biosimilar, Product Type & Application
    Table 12. Global Key Manufacturers of Rituxan (Rituximab) and Biosimilar, Date of Enter into This Industry
    Table 13. Global Manufacturers Market Concentration Ratio (CR5 and HHI)
    Table 14. Global Rituxan (Rituximab) and Biosimilar by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Rituxan (Rituximab) and Biosimilar as of 2022)
    Table 15. Manufacturers Mergers & Acquisitions, Expansion Plans
    Table 16. Global Rituxan (Rituximab) and Biosimilar Market Size by Region (US$ Million): 2018 VS 2022 VS 2029
    Table 17. Global Rituxan (Rituximab) and Biosimilar Sales by Region (2018-2023) & (K Units)
    Table 18. Global Rituxan (Rituximab) and Biosimilar Sales Market Share by Region (2018-2023)
    Table 19. Global Rituxan (Rituximab) and Biosimilar Sales by Region (2024-2029) & (K Units)
    Table 20. Global Rituxan (Rituximab) and Biosimilar Sales Market Share by Region (2024-2029)
    Table 21. Global Rituxan (Rituximab) and Biosimilar Revenue by Region (2018-2023) & (US$ Million)
    Table 22. Global Rituxan (Rituximab) and Biosimilar Revenue Market Share by Region (2018-2023)
    Table 23. Global Rituxan (Rituximab) and Biosimilar Revenue by Region (2024-2029) & (US$ Million)
    Table 24. Global Rituxan (Rituximab) and Biosimilar Revenue Market Share by Region (2024-2029)
    Table 25. North America Rituxan (Rituximab) and Biosimilar Revenue by Country: 2018 VS 2022 VS 2029 (US$ Million)
    Table 26. North America Rituxan (Rituximab) and Biosimilar Sales by Country (2018-2023) & (K Units)
    Table 27. North America Rituxan (Rituximab) and Biosimilar Sales by Country (2024-2029) & (K Units)
    Table 28. North America Rituxan (Rituximab) and Biosimilar Revenue by Country (2018-2023) & (US$ Million)
    Table 29. North America Rituxan (Rituximab) and Biosimilar Revenue by Country (2024-2029) & (US$ Million)
    Table 30. Europe Rituxan (Rituximab) and Biosimilar Revenue by Country: 2018 VS 2022 VS 2029 (US$ Million)
    Table 31. Europe Rituxan (Rituximab) and Biosimilar Sales by Country (2018-2023) & (K Units)
    Table 32. Europe Rituxan (Rituximab) and Biosimilar Sales by Country (2024-2029) & (K Units)
    Table 33. Europe Rituxan (Rituximab) and Biosimilar Revenue by Country (2018-2023) & (US$ Million)
    Table 34. Europe Rituxan (Rituximab) and Biosimilar Revenue by Country (2024-2029) & (US$ Million)
    Table 35. Asia Pacific Rituxan (Rituximab) and Biosimilar Revenue by Region: 2018 VS 2022 VS 2029 (US$ Million)
    Table 36. Asia Pacific Rituxan (Rituximab) and Biosimilar Sales by Region (2018-2023) & (K Units)
    Table 37. Asia Pacific Rituxan (Rituximab) and Biosimilar Sales by Region (2024-2029) & (K Units)
    Table 38. Asia Pacific Rituxan (Rituximab) and Biosimilar Revenue by Region (2018-2023) & (US$ Million)
    Table 39. Asia Pacific Rituxan (Rituximab) and Biosimilar Revenue by Region (2024-2029) & (US$ Million)
    Table 40. Latin America Rituxan (Rituximab) and Biosimilar Revenue by Country: 2018 VS 2022 VS 2029 (US$ Million)
    Table 41. Latin America Rituxan (Rituximab) and Biosimilar Sales by Country (2018-2023) & (K Units)
    Table 42. Latin America Rituxan (Rituximab) and Biosimilar Sales by Country (2024-2029) & (K Units)
    Table 43. Latin America Rituxan (Rituximab) and Biosimilar Revenue by Country (2018-2023) & (US$ Million)
    Table 44. Latin America Rituxan (Rituximab) and Biosimilar Revenue by Country (2024-2029) & (US$ Million)
    Table 45. Middle East & Africa Rituxan (Rituximab) and Biosimilar Revenue by Country: 2018 VS 2022 VS 2029 (US$ Million)
    Table 46. Middle East & Africa Rituxan (Rituximab) and Biosimilar Sales by Country (2018-2023) & (K Units)
    Table 47. Middle East & Africa Rituxan (Rituximab) and Biosimilar Sales by Country (2024-2029) & (K Units)
    Table 48. Middle East & Africa Rituxan (Rituximab) and Biosimilar Revenue by Country (2018-2023) & (US$ Million)
    Table 49. Middle East & Africa Rituxan (Rituximab) and Biosimilar Revenue by Country (2024-2029) & (US$ Million)
    Table 50. Global Rituxan (Rituximab) and Biosimilar Sales (K Units) by Type (2018-2023)
    Table 51. Global Rituxan (Rituximab) and Biosimilar Sales (K Units) by Type (2024-2029)
    Table 52. Global Rituxan (Rituximab) and Biosimilar Sales Market Share by Type (2018-2023)
    Table 53. Global Rituxan (Rituximab) and Biosimilar Sales Market Share by Type (2024-2029)
    Table 54. Global Rituxan (Rituximab) and Biosimilar Revenue (US$ Million) by Type (2018-2023)
    Table 55. Global Rituxan (Rituximab) and Biosimilar Revenue (US$ Million) by Type (2024-2029)
    Table 56. Global Rituxan (Rituximab) and Biosimilar Revenue Market Share by Type (2018-2023)
    Table 57. Global Rituxan (Rituximab) and Biosimilar Revenue Market Share by Type (2024-2029)
    Table 58. Global Rituxan (Rituximab) and Biosimilar Price (US$/Unit) by Type (2018-2023)
    Table 59. Global Rituxan (Rituximab) and Biosimilar Price (US$/Unit) by Type (2024-2029)
    Table 60. Global Rituxan (Rituximab) and Biosimilar Sales (K Units) by Application (2018-2023)
    Table 61. Global Rituxan (Rituximab) and Biosimilar Sales (K Units) by Application (2024-2029)
    Table 62. Global Rituxan (Rituximab) and Biosimilar Sales Market Share by Application (2018-2023)
    Table 63. Global Rituxan (Rituximab) and Biosimilar Sales Market Share by Application (2024-2029)
    Table 64. Global Rituxan (Rituximab) and Biosimilar Revenue (US$ Million) by Application (2018-2023)
    Table 65. Global Rituxan (Rituximab) and Biosimilar Revenue (US$ Million) by Application (2024-2029)
    Table 66. Global Rituxan (Rituximab) and Biosimilar Revenue Market Share by Application (2018-2023)
    Table 67. Global Rituxan (Rituximab) and Biosimilar Revenue Market Share by Application (2024-2029)
    Table 68. Global Rituxan (Rituximab) and Biosimilar Price (US$/Unit) by Application (2018-2023)
    Table 69. Global Rituxan (Rituximab) and Biosimilar Price (US$/Unit) by Application (2024-2029)
    Table 70. Roche Corporation Information
    Table 71. Roche Description and Business Overview
    Table 72. Roche Rituxan (Rituximab) and Biosimilar Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2023)
    Table 73. Roche Rituxan (Rituximab) and Biosimilar Product
    Table 74. Roche Recent Developments/Updates
    Table 75. Teva Corporation Information
    Table 76. Teva Description and Business Overview
    Table 77. Teva Rituxan (Rituximab) and Biosimilar Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2023)
    Table 78. Teva Rituxan (Rituximab) and Biosimilar Product
    Table 79. Teva Recent Developments/Updates
    Table 80. Pfizer Corporation Information
    Table 81. Pfizer Description and Business Overview
    Table 82. Pfizer Rituxan (Rituximab) and Biosimilar Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2023)
    Table 83. Pfizer Rituxan (Rituximab) and Biosimilar Product
    Table 84. Pfizer Recent Developments/Updates
    Table 85. Amgen Corporation Information
    Table 86. Amgen Description and Business Overview
    Table 87. Amgen Rituxan (Rituximab) and Biosimilar Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2023)
    Table 88. Amgen Rituxan (Rituximab) and Biosimilar Product
    Table 89. Amgen Recent Developments/Updates
    Table 90. Key Raw Materials Lists
    Table 91. Raw Materials Key Suppliers Lists
    Table 92. Rituxan (Rituximab) and Biosimilar Distributors List
    Table 93. Rituxan (Rituximab) and Biosimilar Customers List
    Table 94. Rituxan (Rituximab) and Biosimilar Market Trends
    Table 95. Rituxan (Rituximab) and Biosimilar Market Drivers
    Table 96. Rituxan (Rituximab) and Biosimilar Market Challenges
    Table 97. Rituxan (Rituximab) and Biosimilar Market Restraints
    Table 98. Research Programs/Design for This Report
    Table 99. Key Data Information from Secondary Sources
    Table 100. Key Data Information from Primary Sources
List of Figures
    Figure 1. Product Picture of Rituxan (Rituximab) and Biosimilar
    Figure 2. Global Rituxan (Rituximab) and Biosimilar Market Value Comparison by Type (2023-2029) & (US$ Million)
    Figure 3. Global Rituxan (Rituximab) and Biosimilar Market Share by Type in 2022 & 2029
    Figure 4. Brand Product Picture
    Figure 5. Biosimilar Product Picture
    Figure 6. Global Rituxan (Rituximab) and Biosimilar Market Value Comparison by Application (2023-2029) & (US$ Million)
    Figure 7. Global Rituxan (Rituximab) and Biosimilar Market Share by Application in 2022 & 2029
    Figure 8. Child
    Figure 9. Adult
    Figure 10. Global Rituxan (Rituximab) and Biosimilar Revenue, (US$ Million), 2018 VS 2022 VS 2029
    Figure 11. Global Rituxan (Rituximab) and Biosimilar Market Size (2018-2029) & (US$ Million)
    Figure 12. Global Rituxan (Rituximab) and Biosimilar Sales (2018-2029) & (K Units)
    Figure 13. Global Rituxan (Rituximab) and Biosimilar Average Price (US$/Unit) & (2018-2029)
    Figure 14. Rituxan (Rituximab) and Biosimilar Report Years Considered
    Figure 15. Rituxan (Rituximab) and Biosimilar Sales Share by Manufacturers in 2022
    Figure 16. Global Rituxan (Rituximab) and Biosimilar Revenue Share by Manufacturers in 2022
    Figure 17. The Global 5 and 10 Largest Rituxan (Rituximab) and Biosimilar Players: Market Share by Revenue in 2022
    Figure 18. Rituxan (Rituximab) and Biosimilar Market Share by Company Type (Tier 1, Tier 2 and Tier 3): 2018 VS 2022
    Figure 19. Global Rituxan (Rituximab) and Biosimilar Market Size by Region (US$ Million): 2018 VS 2022 VS 2029
    Figure 20. North America Rituxan (Rituximab) and Biosimilar Sales Market Share by Country (2018-2029)
    Figure 21. North America Rituxan (Rituximab) and Biosimilar Revenue Market Share by Country (2018-2029)
    Figure 22. United States Rituxan (Rituximab) and Biosimilar Revenue Growth Rate (2018-2029) & (US$ Million)
    Figure 23. Canada Rituxan (Rituximab) and Biosimilar Revenue Growth Rate (2018-2029) & (US$ Million)
    Figure 24. Europe Rituxan (Rituximab) and Biosimilar Sales Market Share by Country (2018-2029)
    Figure 25. Europe Rituxan (Rituximab) and Biosimilar Revenue Market Share by Country (2018-2029)
    Figure 26. Germany Rituxan (Rituximab) and Biosimilar Revenue Growth Rate (2018-2029) & (US$ Million)
    Figure 27. France Rituxan (Rituximab) and Biosimilar Revenue Growth Rate (2018-2029) & (US$ Million)
    Figure 28. U.K. Rituxan (Rituximab) and Biosimilar Revenue Growth Rate (2018-2029) & (US$ Million)
    Figure 29. Italy Rituxan (Rituximab) and Biosimilar Revenue Growth Rate (2018-2029) & (US$ Million)
    Figure 30. Russia Rituxan (Rituximab) and Biosimilar Revenue Growth Rate (2018-2029) & (US$ Million)
    Figure 31. Asia Pacific Rituxan (Rituximab) and Biosimilar Sales Market Share by Region (2018-2029)
    Figure 32. Asia Pacific Rituxan (Rituximab) and Biosimilar Revenue Market Share by Region (2018-2029)
    Figure 33. China Rituxan (Rituximab) and Biosimilar Revenue Growth Rate (2018-2029) & (US$ Million)
    Figure 34. Japan Rituxan (Rituximab) and Biosimilar Revenue Growth Rate (2018-2029) & (US$ Million)
    Figure 35. South Korea Rituxan (Rituximab) and Biosimilar Revenue Growth Rate (2018-2029) & (US$ Million)
    Figure 36. India Rituxan (Rituximab) and Biosimilar Revenue Growth Rate (2018-2029) & (US$ Million)
    Figure 37. Australia Rituxan (Rituximab) and Biosimilar Revenue Growth Rate (2018-2029) & (US$ Million)
    Figure 38. China Taiwan Rituxan (Rituximab) and Biosimilar Revenue Growth Rate (2018-2029) & (US$ Million)
    Figure 39. Southeast Asia Rituxan (Rituximab) and Biosimilar Revenue Growth Rate (2018-2029) & (US$ Million)
    Figure 40. Latin America Rituxan (Rituximab) and Biosimilar Sales Market Share by Country (2018-2029)
    Figure 41. Latin America Rituxan (Rituximab) and Biosimilar Revenue Market Share by Country (2018-2029)
    Figure 42. Mexico Rituxan (Rituximab) and Biosimilar Revenue Growth Rate (2018-2029) & (US$ Million)
    Figure 43. Brazil Rituxan (Rituximab) and Biosimilar Revenue Growth Rate (2018-2029) & (US$ Million)
    Figure 44. Argentina Rituxan (Rituximab) and Biosimilar Revenue Growth Rate (2018-2029) & (US$ Million)
    Figure 45. Middle East & Africa Rituxan (Rituximab) and Biosimilar Sales Market Share by Country (2018-2029)
    Figure 46. Middle East & Africa Rituxan (Rituximab) and Biosimilar Revenue Market Share by Country (2018-2029)
    Figure 47. Turkey Rituxan (Rituximab) and Biosimilar Revenue Growth Rate (2018-2029) & (US$ Million)
    Figure 48. Saudi Arabia Rituxan (Rituximab) and Biosimilar Revenue Growth Rate (2018-2029) & (US$ Million)
    Figure 49. UAE Rituxan (Rituximab) and Biosimilar Revenue Growth Rate (2018-2029) & (US$ Million)
    Figure 50. Global Sales Market Share of Rituxan (Rituximab) and Biosimilar by Type (2018-2029)
    Figure 51. Global Revenue Market Share of Rituxan (Rituximab) and Biosimilar by Type (2018-2029)
    Figure 52. Global Rituxan (Rituximab) and Biosimilar Price (US$/Unit) by Type (2018-2029)
    Figure 53. Global Sales Market Share of Rituxan (Rituximab) and Biosimilar by Application (2018-2029)
    Figure 54. Global Revenue Market Share of Rituxan (Rituximab) and Biosimilar by Application (2018-2029)
    Figure 55. Global Rituxan (Rituximab) and Biosimilar Price (US$/Unit) by Application (2018-2029)
    Figure 56. Rituxan (Rituximab) and Biosimilar Value Chain
    Figure 57. Rituxan (Rituximab) and Biosimilar Production Process
    Figure 58. Channels of Distribution (Direct Vs Distribution)
    Figure 59. Distributors Profiles
    Figure 60. Bottom-up and Top-down Approaches for This Report
    Figure 61. Data Triangulation
    Figure 62. Key Executives Interviewed
SELECT A FORMAT
Added to Cart
Electronic (PDF)

$2900

This license allows only one user to access the PDF.
Electronic (PDF)

$4350

This license allows 1 - 5 user to access the PDF, license is suitable for small groups of 5 users working together
Electronic (PDF)

$5800

This license allows users/teams in a same Enterprise to use this report, various departments within an enterpise can use this report
Add to Cart
Buy Now (15% Discount)

OUR CUSTOMER

Nano Dimension

SIMILAR REPORTS